Do analysts rate CAPN or AIKI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cayson Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, CAPN or AIKI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cayson Acquisition N/A N/A N/A N/A N/A AIkido Pharma N/A N/A -$7.17M -$3.88 N/A

Is CAPN or AIKI more profitable?

Cayson Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Cayson Acquisition N/A N/A N/A AIkido Pharma N/A -18.21% -16.94%

Do analysts rate AIKI or PLUT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Plutus Financial Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, AIKI or PLUT?

Plutus Financial Group has higher revenue and earnings than AIkido Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AIkido Pharma N/A N/A -$7.17M -$3.88 N/A Plutus Financial Group $1.34M 29.90 -$5.06M N/A N/A

Is AIKI or PLUT more profitable?

Plutus Financial Group's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Plutus Financial Group N/A N/A N/A

Do analysts recommend AIKI or MDBH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MDB Capital 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AIKI or MDBH more profitable?

AIkido Pharma's return on equity of -18.21% beat MDB Capital's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% MDB Capital N/A -39.77% -38.48%

Do analysts rate GRAN or AIKI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grande Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, GRAN or AIKI?

Grande Group has higher revenue and earnings than AIkido Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grande Group $1.81M 18.23 -$3.47M N/A N/A AIkido Pharma N/A N/A -$7.17M -$3.88 N/A

Is GRAN or AIKI more profitable?

Grande Group's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Grande Group N/A N/A N/A AIkido Pharma N/A -18.21% -16.94%

Do analysts prefer AIKI or BCG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Binah Capital Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

AIkido Pharma (AIKI) Competitors

$2.56 -0.03 (-1.16%)

As of 08/25/2026

Compare

AIKI vs. CAPN, PLUT, MDBH, GRAN, and BCG

Should you buy AIkido Pharma stock or one of its competitors? AIkido Pharma's main competitors and comparable companies include Cayson Acquisition (CAPN), Plutus Financial Group (PLUT), MDB Capital (MDBH), Grande Group (GRAN), and Binah Capital Group (BCG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "investment banking & brokerage" industry.

How does AIkido Pharma compare to Cayson Acquisition?

Cayson Acquisition (NASDAQ:CAPN) and AIkido Pharma (NASDAQ:AIKI) are both small-cap finance companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

Cayson Acquisition has a beta of -0.08, indicating that its stock price is 108% less volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

Cayson Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cayson Acquisition	N/A	N/A	N/A
AIkido Pharma	N/A	-18.21%	-16.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cayson Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Cayson Acquisition had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for Cayson Acquisition and 0 mentions for AIkido Pharma. Cayson Acquisition's average media sentiment score of 1.89 beat AIkido Pharma's score of 0.00 indicating that Cayson Acquisition is being referred to more favorably in the media.

Company	Overall Sentiment
Cayson Acquisition	Very Positive
AIkido Pharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cayson Acquisition	N/A	N/A	N/A	N/A	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

10.9% of AIkido Pharma shares are held by institutional investors. 22.1% of Cayson Acquisition shares are held by company insiders. Comparatively, 8.6% of AIkido Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Cayson Acquisition beats AIkido Pharma on 6 of the 8 factors compared between the two stocks.

How does AIkido Pharma compare to Plutus Financial Group?

AIkido Pharma (NASDAQ:AIKI) and Plutus Financial Group (NASDAQ:PLUT) are both small-cap finance companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

10.9% of AIkido Pharma shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Plutus Financial Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Plutus Financial Group had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for Plutus Financial Group and 0 mentions for AIkido Pharma. Plutus Financial Group's average media sentiment score of 1.89 beat AIkido Pharma's score of 0.00 indicating that Plutus Financial Group is being referred to more favorably in the news media.

Company	Overall Sentiment
AIkido Pharma	Neutral
Plutus Financial Group	Very Positive

Plutus Financial Group's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Plutus Financial Group	N/A	N/A	N/A

Plutus Financial Group has higher revenue and earnings than AIkido Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Plutus Financial Group	$1.34M	29.90	-$5.06M	N/A	N/A

AIkido Pharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Plutus Financial Group has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

Summary

Plutus Financial Group beats AIkido Pharma on 8 of the 10 factors compared between the two stocks.

How does AIkido Pharma compare to MDB Capital?

AIkido Pharma (NASDAQ:AIKI) and MDB Capital (NASDAQ:MDBH) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability.

AIkido Pharma has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, MDB Capital has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 0.4% of MDB Capital shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 55.8% of MDB Capital shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MDB Capital	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, MDB Capital had 1 more articles in the media than AIkido Pharma. MarketBeat recorded 1 mentions for MDB Capital and 0 mentions for AIkido Pharma. MDB Capital's average media sentiment score of 1.89 beat AIkido Pharma's score of 0.00 indicating that MDB Capital is being referred to more favorably in the news media.

Company	Overall Sentiment
AIkido Pharma	Neutral
MDB Capital	Very Positive

AIkido Pharma's return on equity of -18.21% beat MDB Capital's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
MDB Capital	N/A	-39.77%	-38.48%

AIkido Pharma has higher earnings, but lower revenue than MDB Capital. MDB Capital is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
MDB Capital	$4.91M	6.38	-$21.25M	-$2.18	N/A

Summary

MDB Capital beats AIkido Pharma on 7 of the 12 factors compared between the two stocks.

How does AIkido Pharma compare to Grande Group?

Grande Group (NASDAQ:GRAN) and AIkido Pharma (NASDAQ:AIKI) are both small-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Grande Group has higher revenue and earnings than AIkido Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grande Group	$1.81M	18.23	-$3.47M	N/A	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

10.9% of AIkido Pharma shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grande Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Grande Group had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for Grande Group and 0 mentions for AIkido Pharma. Grande Group's average media sentiment score of 1.44 beat AIkido Pharma's score of 0.00 indicating that Grande Group is being referred to more favorably in the media.

Company	Overall Sentiment
Grande Group	Positive
AIkido Pharma	Neutral

Grande Group's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grande Group	N/A	N/A	N/A
AIkido Pharma	N/A	-18.21%	-16.94%

Summary

Grande Group beats AIkido Pharma on 7 of the 9 factors compared between the two stocks.

How does AIkido Pharma compare to Binah Capital Group?

AIkido Pharma (NASDAQ:AIKI) and Binah Capital Group (NASDAQ:BCG) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Binah Capital Group has higher revenue and earnings than AIkido Pharma. AIkido Pharma is trading at a lower price-to-earnings ratio than Binah Capital Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Binah Capital Group	$187.14M	0.13	$2.31M	$0.18	8.06

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 5.0% of Binah Capital Group shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 7.8% of Binah Capital Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Binah Capital Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Binah Capital Group had 3 more articles in the media than AIkido Pharma. MarketBeat recorded 3 mentions for Binah Capital Group and 0 mentions for AIkido Pharma. Binah Capital Group's average media sentiment score of 0.54 beat AIkido Pharma's score of 0.00 indicating that Binah Capital Group is being referred to more favorably in the news media.

Company	Overall Sentiment
AIkido Pharma	Neutral
Binah Capital Group	Positive

AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Binah Capital Group has a beta of 0.27, indicating that its share price is 73% less volatile than the broader market.

Binah Capital Group has a net margin of 2.17% compared to AIkido Pharma's net margin of 0.00%. Binah Capital Group's return on equity of 195.38% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Binah Capital Group	2.17%	195.38%	5.95%

Summary

Binah Capital Group beats AIkido Pharma on 10 of the 13 factors compared between the two stocks.

Get AIkido Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIKI vs. The Competition

Export

Metric	AIkido Pharma	Capital Markets Industry	Finance Sector	NASDAQ Exchange
Market Cap	$14.04M	$5.73B	$14.10B	$12.81B
Dividend Yield	N/A	7.39%	5.89%	11.02%
P/E Ratio	-0.66	32.55	26.71	24.12
Price / Sales	N/A	1,235.69	518.26	89.48
Price / Cash	N/A	48.45	39.14	53.65
Price / Book	0.13	2.13	2.18	6.20
Net Income	-$7.17M	$417.46M	$1.31B	$348.07M
7 Day Performance	-5.54%	0.84%	1.51%	1.11%
1 Month Performance	-3.03%	2.08%	2.57%	4.27%
1 Year Performance	-59.94%	8.05%	11.60%	16.48%

AIkido Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIKI AIkido Pharma	N/A	$2.56 -1.2%	N/A	-58.8%	$14.04M	N/A	N/A	4
CAPN Cayson Acquisition	0.8401 of 5 stars	$11.15 -0.1%	N/A	+8.0%	$58.98M	N/A	N/A	N/A	News Coverage Positive News
PLUT Plutus Financial Group	0.6537 of 5 stars	$2.72 -0.2%	N/A	-4.0%	$41.75M	$1.34M	N/A	10	Positive News
MDBH MDB Capital	0.7324 of 5 stars	$3.17 +3.6%	N/A	-9.3%	$32.65M	$4.91M	N/A	40	Positive News Gap Down
GRAN Grande Group	0.7385 of 5 stars	$1.30 -3.7%	N/A	-62.1%	$32.01M	$1.81M	N/A	20	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIKI) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AIkido Pharma (AIKI) Competitors

AIKI vs. CAPN, PLUT, MDBH, GRAN, and BCG

How does AIkido Pharma compare to Cayson Acquisition?

Summary

How does AIkido Pharma compare to Plutus Financial Group?

Summary

How does AIkido Pharma compare to MDB Capital?

Summary

How does AIkido Pharma compare to Grande Group?

Summary

How does AIkido Pharma compare to Binah Capital Group?

Summary

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AIkido Pharma (AIKI) Competitors

AIKI vs. CAPN, PLUT, MDBH, GRAN, and BCG

How does AIkido Pharma compare to Cayson Acquisition?

Which has more volatility and risk, CAPN or AIKI?

Is CAPN or AIKI more profitable?

Do analysts rate CAPN or AIKI?

Does the media refer more to CAPN or AIKI?

Which has higher valuation and earnings, CAPN or AIKI?

Do institutionals & insiders have more ownership in CAPN or AIKI?

Summary

How does AIkido Pharma compare to Plutus Financial Group?

Do insiders and institutionals have more ownership in AIKI or PLUT?

Do analysts rate AIKI or PLUT?

Does the media favor AIKI or PLUT?

Is AIKI or PLUT more profitable?

Which has higher valuation & earnings, AIKI or PLUT?

Which has more risk and volatility, AIKI or PLUT?

Summary

How does AIkido Pharma compare to MDB Capital?

Which has more risk & volatility, AIKI or MDBH?

Do insiders and institutionals believe in AIKI or MDBH?

Do analysts recommend AIKI or MDBH?

Does the media prefer AIKI or MDBH?

Is AIKI or MDBH more profitable?

Which has preferable valuation and earnings, AIKI or MDBH?

Summary

How does AIkido Pharma compare to Grande Group?

Which has preferable valuation & earnings, GRAN or AIKI?

Do insiders & institutionals have more ownership in GRAN or AIKI?

Do analysts rate GRAN or AIKI?

Does the media refer more to GRAN or AIKI?

Is GRAN or AIKI more profitable?

Summary

How does AIkido Pharma compare to Binah Capital Group?

Which has stronger valuation and earnings, AIKI or BCG?

Do institutionals and insiders have more ownership in AIKI or BCG?

Do analysts prefer AIKI or BCG?

Does the media favor AIKI or BCG?

Which has more volatility and risk, AIKI or BCG?

Is AIKI or BCG more profitable?

Summary

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools